Cardiology
Research on tirzepatide, a dual GIP/GLP-1 receptor agonist, including SURPASS, SURMOUNT, and cardiovascular-focused substudies.
Synthesized from 9 evidence-backed clinical questions linked to this topic — 2 supporting the intervention, 1 against the intervention.
Does tirzepatide vs dulaglutide improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty≈ Likely no clinically meaningful effecttirzepatide vs dulaglutide
3 studies (0 patients, 1 RCTs) provide low-certainty evidence showing no clinically meaningful effect of tirzepatide for the outcome in Diabetes Mellitus, Type 2.
Does tirzepatide vs dulaglutide improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?
Low Certainty+ Favors benefittirzepatide vs dulaglutide
3 studies (39,897 patients) provide low-certainty evidence for benefit of tirzepatide for the outcome in Diabetes Mellitus, Non-Insulin-Dependent.
Does tirzepatide vs placebo improve Body Weight Change in Obesity?
Low Certainty+ Favors benefittirzepatide vs placebo · Body Weight Change
2 studies (0 patients) provide low-certainty evidence for benefit of tirzepatide for Body Weight Change in Obesity.
No claims extracted for this topic
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Questions where the synthesized consensus has shifted as new trials were indexed.
Tirzepatide and <scp>SGLT2</scp> Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era
Endocrinology Diabetes & Metabolism — Mohamed Z — Jul 2026
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure
Diabetes and Vascular Disease Research — Mortada I — Jul 2026
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Tirzepatide (also known as Tirzepatide, Mounjaro, Zepbound). Research on tirzepatide, a dual GIP/GLP-1 receptor agonist, including SURPASS, SURMOUNT, and cardiovascular-focused substudies.
Synapse tracks 1 specific clinical question in Tirzepatide, synthesizing the evidence for it independently: "Does tirzepatide vs placebo improve Body Weight Change in Obesity?".
As of 2026-08-14, the scientific consensus on Tirzepatide is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/peptide-tirzepatide.
Deterministic synthesis from Synapse's enriched corpus — 72 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Tirzepatide paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Tirzepatide papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Cardiovascular Toxicology — Khatami S — Jul 2026
